Roche Receives FDA Approval For The First Companion Diagnostic To Identify Patients With HER2-Ultralow Metastatic Breast Cancer Eligible For ENHERTU
As seen in the DESTINY-Breast06 trial, a pproximately 20-25 percent of hormone receptor (HR)-positive, HER2- ...
FDA approves Datroway for HR-positive, HER2-negative breast cancer
The U.S. Food and Drug Administration has approved Datroway (datopotamab deruxtecan-dlnk) for adult patients with ...
FDA approves new type of nonopioid painkiller for acute pain
The drug, Journavx, from Vertex Pharmaceuticals, reduced pain after surgery in clinical trials. Experts hope it can lead to fewer opioid prescriptions.
Alaska Dispatch News19h
FDA approves new painkiller aimed at eliminating risks of addiction associated with opioids
WASHINGTON — Federal officials on Thursday approved a new type of pain drug designed to eliminate the risks of addiction and ...
US FDA approves Vertex's non-opioid painkiller
The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health regulator ...
BioPharma Dive1d
Enhertu, with new OK, set to supplant chemo in HER2-low breast cancer
The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...
Hosted on MSN1d
FDA expands Enhertu approval to include HER2-ultralow breast cancer patients
Enhertu first secured approval in 2019 for patients with high levels of HER2, a protein that promotes cancer cell growth. In ...
ABC72d
FDA approves Ozempic to reduce risks from chronic kidney disease in diabetes patients
Ozempic has now also been approved by the US Food and Drug Administration to reduce certain risks associated with chronic ...
chromatographyonline2d
Characterizing Antibody-Drug Conjugates Using Mass Spectrometry
Scientists from the National Institutes for Food and Drug Control have characterized antibody-drug conjugates (ADCs) using ...